Maryland Fire Departments Awarded $520,000 for Cancer Screenings using 20/20 BioLabs’ OneTest ™ Multi-Cancer Early Detection Blood Test

State-Funded Screening Initiative Highlights Growing Public Sector Support for Innovative Cancer Detection Tools GAITHERSBURG, Md., March 27, ...
Seeking Alpha

20/20 BioLabs Launches OneTest for Longevity Blood Test and Chronic Disease Risk Assessment and Management Solution Built with IBM AI Capabilities

Recently Nasdaq-Listed Company Introduces Longevity Blood Test Integrating Inflammatory Biomarkers, Dietary Habits, and Curated Scientific Research to Deliver Personalized Health Insights GAITHERSBURG ...
TMCnet

20/20 BioLabs Announces Exclusive U.S. License Agreement with ROKIT Healthcare to Integrate Advanced CKD Prediction Technology into Its Longevity Test Program

Expands OneTest for Longevity with Chronic Kidney Disease Risk Assessment GAITHERSBURG, Md., March 24, 2026 (GLOBE NEWSWIRE) ...
Yahoo Finance

20/20 BioLabs Debuts Trading on Nasdaq Under Ticker Symbol "AIDX" Following 3 Consecutive Years of Sales Growth

Company Ready to Scale Growth through OneTest™ AI-Powered Blood Tests for Cancer and Longevity GAITHERSBURG, Md., Feb. 19, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc. (Nasdaq: AIDX), an early market ...
Investing

20/20 BioLabs begins trading on Nasdaq under AIDX ticker

GAITHERSBURG, Md. - 20/20 BioLabs, Inc. (NASDAQ:AIDX) began trading on the Nasdaq Capital Market Thursday under the ticker symbol AIDX, marking the company’s transition to a publicly traded entity.
Finanznachrichten

20/20 Biolabs Inc.: 20/20 BioLabs Debuts Trading on Nasdaq Under Ticker Symbol "AIDX" Following 3 Consecutive Years of Sales Growth

Company Ready to Scale Growth through OneTest AI-Powered Blood Tests for Cancer and Longevity GAITHERSBURG, Md., Feb. 19, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc. (Nasdaq: AIDX), an early market ...